Suppr超能文献

在一项皮肤利什曼病临床试验中,与使用葡甲胺锑酸盐的不同治疗方案依从性相关的因素。

Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

作者信息

Ribeiro Madelon Novato, Pimentel Maria Inês Fernandes, Schubach Armando de Oliveira, Oliveira Raquel de Vasconcellos Carvalhães de, Teixeira José Liporage, Leite Madson Pedro da Silva, Fonseca Monique, Santos Ginelza Peres Lima dos, Salgueiro Mariza Matos, Ferreira e Vasconcellos Erica de Camargo, Lyra Marcelo Rosandiski, Saheki Mauricio Naoto, Valete-Rosalino Claudia Maria

机构信息

Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.

出版信息

Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):291-6. doi: 10.1590/s0036-46652014000400004.

Abstract

The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test (without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods.

摘要

疾病治疗的良好结果受治疗依从性的影响。我们的目标是评估与参与一项关于葡萄糖酸锑钠(MA)治疗皮肤利什曼病(CL)的标准与替代治疗方案等效性临床试验的患者治疗依从性相关的因素,该研究在里约热内卢州进行。2008年至2011年期间,使用问卷对57例CL患者进行了访谈,以收集社会经济数据。采用以下方法监测依从性:计算剩余药瓶数、监测卡、Morisky测试和改良Morisky测试(不包括关于服药时间的问题);我们观察到的依从率分别为82.1%(药瓶归还)、86.0%(监测卡)、66.7%(Morisky测试)和86.0%(改良Morisky测试)。药瓶计数法与监测卡及改良Morisky测试之间存在很强的相关性。观察到治疗依从性较高与低剂量MA以及同一房间睡眠人数较少之间存在显著关联。我们建议使用改良Morisky测试来评估MA治疗CL的治疗依从性,因为与其他方法相比,它是一种简单且性能良好的方法。

相似文献

1
Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):291-6. doi: 10.1590/s0036-46652014000400004.
2
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Rev Soc Bras Med Trop. 2016 Nov-Dec;49(6):774-776. doi: 10.1590/0037-8682-0213-2016.
4
Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
Trials. 2012 May 17;13:58. doi: 10.1186/1745-6215-13-58.
5
Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Br J Dermatol. 1998 Feb;138(2):370-1. doi: 10.1046/j.1365-2133.1998.02105.x.
6
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005459. doi: 10.1371/journal.pntd.0005459. eCollection 2017 Apr.
8
Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Int J Dermatol. 1999 Aug;38(8):607-9. doi: 10.1046/j.1365-4362.1999.00769.x.
9
Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
Rev Inst Med Trop Sao Paulo. 2014 Jul-Aug;56(4):361-2. doi: 10.1590/s0036-46652014000400016.

引用本文的文献

2
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834. doi: 10.1002/14651858.CD004834.pub3.
3
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
PLoS Negl Trop Dis. 2020 Feb 28;14(2):e0008050. doi: 10.1371/journal.pntd.0008050. eCollection 2020 Feb.
5
How cutaneous leishmaniasis and treatment impacts in the patients' lives: A cross-sectional study.
PLoS One. 2019 Jan 25;14(1):e0211374. doi: 10.1371/journal.pone.0211374. eCollection 2019.
6
Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania.
Front Immunol. 2015 Oct 13;6:524. doi: 10.3389/fimmu.2015.00524. eCollection 2015.

本文引用的文献

1
Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers.
Curr Ther Res Clin Exp. 2006 May;67(3):193-203. doi: 10.1016/j.curtheres.2006.06.005.
2
Knowledge of the patients regarding leprosy and adherence to treatment.
Braz J Infect Dis. 2012 Sep-Oct;16(5):472-5. doi: 10.1016/j.bjid.2012.04.002. Epub 2012 Sep 12.
4
Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.
PLoS Negl Trop Dis. 2012;6(6):e1656. doi: 10.1371/journal.pntd.0001656. Epub 2012 Jun 12.
6
[Directly observed therapy using home-based supervisors for treating tuberculosis in Vitória, Brazil].
J Bras Pneumol. 2008 Jul;34(7):506-13. doi: 10.1590/s1806-37132008000700011.
7
A study of the excretion of organic antimonials using a polarographic procedure.
Biochem J. 1943 Jul;37(2):198-209. doi: 10.1042/bj0370198.
8
Adherence to medication.
N Engl J Med. 2005 Aug 4;353(5):487-97. doi: 10.1056/NEJMra050100.
9
Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.
Rev Soc Bras Med Trop. 2005 May-Jun;38(3):213-7. doi: 10.1590/s0037-86822005000300001. Epub 2005 May 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验